- Home
- FLGT vs VSTM Comparison
FLGT vs VSTM Comparison
Compare FLGT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- VSTM
- Stock Information
- Founded
- FLGT 2011
- VSTM 2010
- Country
- FLGT United States
- VSTM United States
- Employees
- FLGT N/A
- VSTM N/A
- Industry
- FLGT Medical Specialities
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- FLGT Health Care
- VSTM Health Care
- Exchange
- FLGT Nasdaq
- VSTM Nasdaq
- Market Cap
- FLGT 697.3M
- VSTM 581.6M
- IPO Year
- FLGT 2016
- VSTM 2012
- Fundamental
- Price
- FLGT $30.25
- VSTM $10.71
- Analyst Decision
- FLGT Buy
- VSTM Strong Buy
- Analyst Count
- FLGT 3
- VSTM 9
- Target Price
- FLGT $28.33
- VSTM $13.38
- AVG Volume (30 Days)
- FLGT 411.7K
- VSTM 2.8M
- Earning Date
- FLGT 11-07-2025
- VSTM 11-04-2025
- Dividend Yield
- FLGT N/A
- VSTM N/A
- EPS Growth
- FLGT N/A
- VSTM N/A
- EPS
- FLGT N/A
- VSTM N/A
- Revenue
- FLGT $315,549,000.00
- VSTM $13,379,000.00
- Revenue This Year
- FLGT $15.19
- VSTM $88.60
- Revenue Next Year
- FLGT $10.58
- VSTM $416.99
- P/E Ratio
- FLGT N/A
- VSTM N/A
- Revenue Growth
- FLGT 13.61
- VSTM 33.79
- 52 Week Low
- FLGT $14.57
- VSTM $3.46
- 52 Week High
- FLGT $31.04
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- FLGT 71.79
- VSTM 65.97
- Support Level
- FLGT $28.65
- VSTM $7.29
- Resistance Level
- FLGT $31.04
- VSTM $10.45
- Average True Range (ATR)
- FLGT 1.33
- VSTM 0.68
- MACD
- FLGT 0.21
- VSTM 0.23
- Stochastic Oscillator
- FLGT 87.98
- VSTM 93.53
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.